Momenta seeks restraining order against Amphastar/Watson on a 2nd generic Lovenox
This article was originally published in Scrip
Executive Summary
Momenta Pharmaceuticals is seeking a temporary restraining order and preliminary injunction to prevent Watson and Amphastar from launching their competing version of generic Lovenox (enoxaparin) in the US market, based on patents Momenta owns on manufacturing that it claims are infringed. But it is well known that a high bar exists for such injunctions.